David B. Agus, MD

Professor of Medicine and Biomedical Engineering

Director, Lawrence J. Ellison Institute for Transformative Medicine of USC

Director, USC Center for Applied Molecular Medicine

Websites

Is this your profile? Click to edit

Overview

David B. Agus is a professor of medicine and engineering at the University of Southern California’s Keck School of Medicine and Viterbi School of Engineering. He is the founding director and CEO of the Lawrence J. Ellison Institute for Transformative Medicine. A medical oncologist, Dr. Agus leads a multidisciplinary team of researchers dedicated to the development and use of technologies to guide doctors in making health-care decisions tailored to individual needs. An international leader in new technologies and approaches for personalized healthcare, Dr. Agus serves in leadership roles at the World Economic Forum and the Global Health Security Consortium. He is also a CBS News contributor. Dr. Agus’ three books “The End of Illness”, “A Short Guide to a Long Life” and “The Lucky Years: How to Thrive in the Brave New World of Health” are all New York Times and international bestsellers. Dr. Agus graduated cum laude with honors in molecular biology from Princeton University, and received his medical degree from the University of Pennsylvania School of Medicine. He completed his medical internship and residency training at Johns Hopkins Hospital and fellowship at Memorial Sloan-Kettering Cancer Center.

Awards

American Cancer Society: Physician Research Award, 1996
– 2001
Sloan-Kettering Institute: Clinical Scholar Award, 1996
American Cancer Society: Clinical Oncology Fellowship Award, 1994
HealthNetwork Foundation: Excellence Award, 2008
Geoffrey Beene Foundation: Rock Stars of Science™, 2009
Biotech Humanitarian Award: Selected Judge, 2009
USC Association of Trojan Leagues: Outstanding Service Award, 2013
American College of Physicians: Fellow, 2016
Ellis Island Medal of Honor: Medalist, 2017

Research Funding

(PQB6)An Integrative Computational and Bioengineered Tissue Model of Metastasis
NIH · R01CA180149 · Sep 5, 2013 – Jul 31, 2018 · Role: Principal Investigator
UCLA SPORE in Prostate Cancer
NIH · P50CA092131 · Jul 1, 2001 – Aug 31, 2024 · Role: Co-Principal Investigator

Media

Sixty-five simple rules to maintain good health (1/8/2014)
Agus relishes his role as a health care rebel (10/11/2012)
Agus' book focuses on new view of health (1/17/2012)
USC Welcomes Oncologist David Agus (06/30/2009)

Publications

PPARgamma signaling: one size fits all? Cell Cycle. 2004 Nov; 3(11):1352-4. Jain A, Agus DB . View in PubMed
CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. Prostate. 2004 Nov 01; 61(3):228-35.. View in PubMed
Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma. Cancer Cell. 2004 Jun; 5(6):565-74.. View in PubMed
Ductal adenocarcinoma of the prostate. Clin Adv Hematol Oncol. 2004 Jun; 2(6):393-5.. View in PubMed
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 2004 Feb 01; 22(3):537-56.. View in PubMed
Targeting the HER-kinase axis in cancer. Semin Oncol. 2004 Feb; 31(1 Suppl 3):9-20.. View in PubMed
Update on HER-kinase-directed therapy in prostate cancer. Clin Adv Hematol Oncol. 2004 Jan; 2(1):53-6.. View in PubMed
Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res. 2003 Jul 15; 63(14):4196-203.. View in PubMed
Effects of the herbal extract PC-SPES on microtubule dynamics and paclitaxel-mediated prostate tumor growth inhibition. J Natl Cancer Inst. 2002 Nov 06; 94(21):1641-7.. View in PubMed
Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin Cancer Res. 2002 Oct; 8(10):3226-31.. View in PubMed